17-May-2024
Dr. Reddy’s Addresses USFDA Inspection Observations
TipRanks (Fri, 17-May 9:57 AM ET)
Dr. Reddy’s Engages Investors in Upcoming Conferences
TipRanks (Wed, 15-May 2:57 PM ET)
Dr. Reddy's Q4 & Full Year FY24 Financial Results
Business Wire (Tue, 7-May 10:31 AM ET)
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
Business Wire (Fri, 3-May 8:00 AM ET)
Globe Newswire (Fri, 22-Mar 7:00 AM ET)
Dr. Reddy's Laboratories launches Versavo (bevacizumab) in the UK
Business Wire (Tue, 19-Mar 7:00 AM ET)
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
DR Reddy's Laboratories trades on the NYSE stock market under the symbol RDY.
As of May 17, 2024, RDY stock price declined to $68.26 with 198,636 million shares trading.
RDY has a beta of 0.23, meaning it tends to be less sensitive to market movements. RDY has a correlation of 0.02 to the broad based SPY ETF.
RDY has a market cap of $11.37 billion. This is considered a Large Cap stock.
Last quarter DR Reddy's Laboratories reported $850 million in Revenue and $.94 earnings per share. This fell short of revenue expectation by $-3 million and exceeded earnings estimates by $.12.
In the last 3 years, RDY stock traded as high as $77.72 and as low as $47.88.
The top ETF exchange traded funds that RDY belongs to (by Net Assets): VWO, VXUS, SPEM, AVEM, VEU.
RDY has underperformed the market in the last year with a price return of +26.8% while the SPY ETF gained +29.1%. RDY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -9.5% and -9.2%, respectively, while the SPY returned +6.3% and +3.6%, respectively.
RDY support price is $68.46 and resistance is $70.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RDY stock will trade within this expected range on the day.